Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net (loss) income	$ (34)	$ 3,838
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Amortization of operating lease right-of-use assets	803	498
Depreciation and amortization	351	336
Deferred income taxes (benefit)	72	(1,530)
Accretion of financing instruments, amortization of prepaid financing costs and other	12	21
Compensation expense on employee stock options	320	369
Unrealized (gain) loss on investment in iBio Stock	(27)	55
Realized loss on sale of iBio Stock	35	0
Bad debt expense	3	13
Gain on disposal of fixed assets	(1)	(22)
Changes in operating assets and liabilities:
Accounts receivable	374	875
Inventories	794	640
Prepaid expenses and other assets	34	(84)
Operating lease obligations	(804)	(501)
Accounts payable	(921)	(218)
Accrued expenses and other current liabilities	221	(199)
Net cash provided by operating activities	1,232	4,091
Cash flows from investing activities:
Purchase of property and equipment	(116)	(486)
Proceeds from sale of iBio Stock	4	0
Proceeds from sale of fixed assets	1	21
Net cash used in investing activities	(111)	(465)
Cash flows from financing activities:
Repayments of advances under revolving credit facility, net	(101)	(2,073)
Proceeds from exercises of stock options	0	34
Repayments under term notes payable	0	(1,466)
Repayments under financed lease obligations	(35)	0
Net cash used in financing activities	(136)	(3,505)
Net increase in cash	985	121
Cash at beginning of fiscal year	331	210
Cash at end of fiscal year	1,316	331
Supplemental disclosures of cash flow information:
Interest	41	113
Income taxes	0	471
Supplemental disclosures of non-cash transactions:
Amount owed on purchase of fixed assets	0	22
Financing on financed lease obligation	0	85
Acquisition of right-of-use asset, net and operating lease obligations, net	1,560	0
Trade in value on like-kind exchanges	$ 0	$ 7